AllAnalyst Report
logoMorningstarOctober 15, 2020

Incyte Corporation: Raising Our Incyte FVE Following Solid Q2 Results and Approval of Blood Cancer Drug Monjuvi

Symbols
INCY
Sector(s)
Healthcare
Rating
Premium
Current Price
$90.56
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE